Retour aux projets

19072.1 IP-LS

19072.1 IP-LS

Résumé

Development of neuroprotective molecules for the treatment of Amyotrophic lateral sclerosis (ALS)

Textes supplémentaires

Abstract

We have recently identified, using a drug-screening platform, a number of molecules that stimulate the activity of astrocytes, a type of glial cells that supports neuronal metabolism. These drugs, which improve neuronal survival and activity, are of particular interest for the treatment of neurodegenerative diseases. Most promising compounds are tested in a mouse model of ALS, as well as cognition/memory. The most effective candidates - whether neuroprotective or cognitive enhancers - will be patented and will represent the core of our Start-up pipeline

Participants

Sylvain Lengacher

Wirtschaftspartner

sylengach@gliapharm.com

Gliapharm SA Sylvain Lengacher Ch. des Mines 9 1202 Geneva GE CH

Pierre Magistretti

Kontaktperson

pierre.magistretti@epfl.ch

EPFL Pierre Magistretti Station 19 1015 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2016-06-30
Date de fin
2018-11-30
Coûts totaux approuvés
CHF 313717.00
Section
60 Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%